anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
D-3,5,31-Triiodothyronine is prepared by the slow iodination of D-3,5-diiodothyronine in an ammonia/methanol mixture with Niodine in potassium iodide solution.  The crude product is obtained by dilution of the reaction mixture with water and addition of a mineral acid after the removal of the bulk of the ammonia and methanol. Purification is achieved by hot filtration of a solution of the crude product in 2N-hydrochloric acid followed by chromatographic separation of the above compound and thyronine on a keiselguhr column using 20% chloroform in n-butanol equilibrated with 0.5 N sodium hydroxide.ALSO:Antihypocholesterolemic compositions comprise, as active ingredient, D-3,5,31-triiodothyronine or a non-toxic, pharmaceutically active salt thereof e.g. the mono- and di-alkali metal, ammonium and lower (C1-) alkyl ammonium salts.  The compositions may be in solid or liquid forms e.g. a tablet, capsule, troche, lozenge, syrup or liquid suspension suitable for oral administration or injection and may contain conventional carriers and flavouring agents.  The active material may also be mixed with the feed or drink of animals for administration thereto.  Additional non-hormonal medicinal ingredients e.g. vitamins, unsaturated fatty acids and lipotropic agents e.g. inositol, betaine, methionic and choline.
PURPOSE: To obtain a skin preparation for external use containing, as active ingredients, Hederacoside and at least one kind of compound selected from L-ascorbic acid compounds, placenta extract, kojic acid compounds, azelaic acid compounds, glucosamine compounds, hydroquinone compounds and tranexamic acid compounds. CONSTITUTION: This skin preparation for external use contains, as active ingredients, 0.001-20wt.% of at least one kind of compound selected from L- ascorbic acid and derivatives therefrom, placenta extract, kojic acid and derivatives therefrom, azelaic acid and derivatives therefrom, glucosamine and derivatives therefrom, hydroquinone glycosides and derivatives therefrom, and tranexamic acid and derivatives therefrom and 0.001-20wt.% of Hederacoside and/or its salt. Combined use of the above two kinds of active ingredients results in the synergistic skin beautifying effect of this skin preparation with high safety. The skin preparation can be made into such formulations as solubilized system e.g. lotion, emulsified system e.g. milky lotion or cream, ointment or dispersion. The Hederacoside is a triterpenoid saponin obtainable from the extract of Sapindus mukurossi Gaertn. or Akebia quinata Decne.
All subjects enrolled will be assigned to receive midodrine. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
Neurovascular coupling (NVC), which mediates rapid increases in cerebral blood flow in response to neuronal activation, is commonly used to map brain activation or dysfunction. Here we tested the reemerging hypothesis that CO2 generated by neuronal metabolism contributes to NVC. We combined functional ultrasound and two-photon imaging in the mouse barrel cortex to specifically examine the onsets of local changes in vessel diameter, blood flow dynamics, vascular/perivascular/intracellular pH, and intracellular calcium signals along the vascular arbor in response to a short and strong CO2 challenge (10 s, 20%) and whisker stimulation. We report that the brief hypercapnia reversibly acidifies all cells of the arteriole wall and the periarteriolar space 3-4 s prior to the arteriole dilation. During this prolonged lag period, NVC triggered by whisker stimulation is not affected by the acidification of the entire neurovascular unit. As it also persists under condition of continuous inflow of CO2, we conclude that CO2 is not involved in NVC.
The invention entitled "Malt supplement Containing Oleocanthal, with Anti- inflammatory, Antioxidant and Anti-cancer Properties" is in the field of extracting and formulating a compound used in food, pharmaceutical, and supplement industries with special applications in biomedicine. Oleocanthal is a polyphenol with significant medicinal and nutritional value, however, no method has been proposed yet for its economic extraction while preserving properties. Moreover, this substance is lost in the debittering process and becomes useless. In this invention, an innovative supercritical process with triple solvents is used to extract quality oleocanthal from the olive fruits at a high rate and the temperature and pressure of 59 °C and 2 MPa, respectively. Interestingly, in this process, the materials used can be collected and used again. The addition of oleocanthal in the boiling stage of the malt extraction process leads to the production of a cost-effective and quality malt drink supplement with antioxidant and anti-cancer properties.
Systems, devices, and methods provide up-to-date defibrillation shock recommendations. In an example method, multiple segments of an electrocardiogram (ECG) of an individual are detected from an individual receiving chest compressions. The multiple segments are evaluated to determine whether the individual is exhibiting a shockable heart rhythm. A medical device outputs a recommendation indicating whether a defibrillation shock is advised based on the most recent determination of the individual's heart rhythm. For example, the medical device outputs an up-to-date recommendation on-demand in response to an input signal from a user. In some examples, the medical device updates the recommendation based on ongoing analysis of the ECG.
The invention discloses a Chicken E.tenella MA2 (Et MA2) gene, a vector thereof, a recombinant strain thereof, a protein thereof, and an application thereof. The amino acid sequence of the EtMA2 protein is represented by SEQ ID No.2. Or the protein is a protein obtained after the amino acid sequence represented by SEQ ID No.2 is subjected to substitution, deletion, and/or addition of one or more amino acids, and/or a protein with terminal modification and with a same activity. The invention also discloses an EtMA2-outsidedomain protein with an amino acid sequence represented by SEQ ID No.4. Or the protein is a protein obtained after the amino acid sequence represented by SEQ ID No.4 is subjected to substitution, deletion, and/or addition of one or more amino acids, and/or a protein with terminal modification and with a same activity. The EtMA2 protein and the EtMA2-outsidedomain protein can be used for preparing eimeria-resisting medicines. Through the immunization of the EtMA2-outsidedomain protein, chicken can be effectively controlled from being infected by E.tenella. Therefore, the dosages of anticoccidial drugs in chicken farms can be greatly reduced, and chicken coccidiosis can be effectively controlled.
Education was given during 8 weeks of study period. After 8 weeks of study, exercise was given as compensation.
Patients receive an initial course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously or IV beginning on day 3 and continuing until blood counts recover. Patients then receive a second course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and oral etoposide on days 1-21. After completion of chemotherapy, patients are evaluated for second therapeutic conventional surgery. Patients who have unresectable disease undergo conformal radiation therapy. Patients who have resectable disease undergo second surgery followed by conformal radiotherapy.
FIELD: cosmetic preparations. SUBSTANCE: composition comprises aqueous liquid carrier with at least one foam-forming anionic polymer and/or one cationic polymer with foam-forming ability, and mixture of propellents containing dimethyl ether in combination with at least another propellent chosen from volatile alkanes, volatile halogenalkanes and their mixtures. Composition is displaced at raised pressure in hermetic container in the form of aerosol and forming the foam spontaneously in contact with surface on which it is applied. Composition is properly applied on hair and allows styling hair-do. EFFECT: higher fixing characteristics. 19 cl, 4 ex
The anticipated 2000 control subjects without obvious coronary stenosis aged≤45years or ≥65years will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
Accurate assessment of pain in neonates in the neonatal intensive care unit (NICU) is vital because of the high prevalence of painful experiences, including both daily procedural pain and postoperative pain, in this population. Exposure of these infants to many mandatory invasive procedures and poor pain management during this time may lead to different results in the short and long term. Every painful application in newborns causes behavioral and physiological instability. Repeated exposure to painful stimuli produces long-term changes in stress-sensitive brain systems such as the hypothalamic-adrenal system and the developing brain. Therefore, evaluation and prevention of pain in newborns is essential. In the NICU, many medical interventions are often performed on infants that are repetitive, painful, but diagnostically necessary. All environmental stress factors can cause physiological changes such as increased pulse, blood pressure, respiratory rate and a decrease in oxygen saturation in newborns. Increasing energy expenditure to overcome these changes may affect physiological functioning, slowing recovery and adversely affecting the organization of the central nervous system (CNS). Heel blood (TC), vascular access (DY), naso and orogastric (NG-OG) catheter insertion, arterial blood collection, tracheal intubation (TE), various rectal procedures, removal of adhesive tapes, umbilical catheter (UK) insertion and removal, Various procedures such as aspiration, chest physiotherapy applications, diaper changing, various hand contacts, and general body care may induce pain responses in newborns. While these responses are associated with low cognitive and motor scores in early childhood, they may result in changes in visual-perceptual ability and somatosensory sensitivity later on. There are many studies in the literature to increase and prove the accuracy of pain assessment tools. However, since the pain treatments used in these studies were also varied, the homogeneity of the evaluations was insufficient. Therefore, more systematic evaluation studies should be conducted on how to improve pain management in NICUs. Finding which of the painful stimuli affects infants more will also guide the use of treatment methods. The aim of this study is to investigate the effects of different procedures applied in the NICU on the pain levels of term and preterm infants.
Usual Dose 

Adults

The initial dose range is 2 mg per day to 3 mg per day. The dose may be adjusted at intervals of 24 hours or greater, in increments of 1 mg per day. The effective dose range is 1 mg per day to 6 mg per day, as studied in the short-term, placebo-controlled trials. In these trials, short-term (3 week) anti-manic efficacy was demonstrated in a flexible dosage range of 1 mg per day to 6 mg per day [see Clinical Studies (14.2, 14.3)]. Risperidone oral solution, doses higher than 6 mg per day were not studied.

Pediatrics 

The initial dose is 0.5 mg once daily, administered as a single-daily dose in the morning or evening. The dose may be adjusted at intervals of 24 hours or greater, in increments of 0.5 mg or 1 mg per day, as tolerated, to the recommended target dose of 1 mg per day to 2.5 mg per day. Although efficacy has been demonstrated in studies of pediatric patients with bipolar mania at doses between 0.5 mg and 6 mg per day, no additional benefit was observed above 2.5 mg per day, and higher doses were associated with more adverse events. Doses higher than 6 mg per day have not been studied.

Patients experiencing persistent somnolence may benefit from administering half the daily dose twice daily.

Maintenance Therapy

There is no body of evidence available from controlled trials to guide a clinician in the longer-term management of a patient who improves during treatment of an acute manic episode with risperidone oral solution. While it is generally agreed that pharmacological treatment beyond an acute response in mania is desirable, both for maintenance of the initial response and for prevention of new manic episodes, there are no systematically obtained data to support the use of risperidone oral solution in such longer-term treatment (i.e. beyond 3 weeks). The physician who elects to use risperidone oral solution for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.
Human and humanized monoclonal antibodies which binds specifically to subunit A of Shiga like toxin II have been developed which are effective to prevent or ameliorate one or more symptoms of HUS in a human. Effective dosages for treatment or prevention range from approximately 0.1 to 5.0 mg of antibody/kg of patient weight. The examples demonstrate the preferred dosage ranges based on the pig model, and what is being tested in phase I clinical trials. Antibodies are preferably transfused over a period of two hours, although this will depend on the patient and the disease state at the time of treatment. Preferred dosages for treatment of humans are between 0.1 mg/kg-5.0 mg/kg of 5C120, or an equivalent dosage of another antibody to subunit A of STX2. In the most preferred embodiments, dosages of 0.1 mg/kg, 0.5 mg/kg, or 5.0 mg/kg of 5C12 (low dose, anticipated therapeutic dose based on animal data and high dose) are administered.
Study Visit 1 (V1): Upon fitting the inclusion criteria, the patient will be randomized to one of the four interventional groups. A member of the study team will collect the initial orthodontics records. These records include two radiographs (a panoramic radiograph and a lateral cephalogram), intraoral and extraoral photographs, and an iTero intraoral digital scan. The scan will be sent directly to the Align Technology Invisalign doctor platform to begin the process of fabricating the desired aligners according to the clinical instructions for the simulated treatment plan by the study team and the randomly assigned group for the patient. Study Visit 2 (V2): 5 weeks following visit 1, Invisalign aligners will be delivered to the included and randomized subjects, and associated treatment rendered. Subjects will be instructed to wear their aligners full-time except while eating, drinking, and brushing and change their aligners as recommended by Invisalign® every week. Study Visit 3 (V3): The trial will end after the patient has completed wearing the first stage of aligners. Final records will be collected: these include iTero intraoral digital scans to construct the 3D digital models, intraoral and extraoral photographs, and radiographs.

To assess the accuracy of the achieved outcomes and compare the outcomes of the four treatment groups, the collected digital models (predicted simulated models and achieved final scanned models) will be superimposed and compared to assess the accuracy and predictability of rotational tooth movement in the included subjects, and treatment outcomes will be evaluated. The differences between the positions of each tooth in the two digital models (predicted from Clincheck and achieved from the final scan) will quantified for rotation: differences of 2° or more rotation will be considered clinically relevant. These values were chosen from the American Board of Orthodontics (ABO) model grading system for case evaluation and other clinical studies.5 Additionally, data related to treatment duration, number of aligners, and number of visits needed to complete the treatment will be gathered and analyzed in a de-identified form.
Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, treatment will be augmented by adding a selective serotonin reuptake inhibitor (SSRI).
A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposome outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a polymer-lipid conjugate for use in promoting fusion between target membranes. The conjugate is composed of a first segment composed of a hydrophilic polymer and a second hydrophobic polymer segment. The second segment is joined to the first segment by a bond effective to release the first segment in response to an existing or an induced physiologic condition. Attached to the second segment is a vesicle-forming lipid member.
Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
Participants in the control group will have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. Although they will not be asked to complete PROs in between clinic visits, they will be asked to respond to a series of HRQOL questionnaires at baseline, at 6 months (±2 weeks) from enrollment, and at completion of neoadjuvant/adjuvant systemic therapy if this date differs from the 6-month time point by more than 4 weeks. A satisfaction questionnaire will also be administered at the end of study.
The Neofect Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It consists of a glove-shaped sensor device and a software application which can be used with either a large screen or a portable tablet. The system includes multiple Activities of Daily Living (ADL)-based training games, and the system tracks the motion and posture of the wearer's distal limb as they participate. Games can be selected to focus on certain movements (such as forearm pronation/supination, wrist flexion/extension, finger flexion/extension, etc.) based on the needs of the wearer. The software includes a smart learning algorithm, in which the computer automatically adjusts to the optimal level of difficulty to balance challenge and motivation. After initial set-up, the device requires no therapist supervision to use.

Patients will be eligible for the study if they have had an ischemic or hemorrhagic stroke and (2) have impaired arm/hand function secondary to the stroke (see below for specific inclusion and exclusion criteria). We will recruit eligible patients from acute care hospitals, acute rehabilitation units, and outpatient facilities. Enrolled patients will be randomized (1:1 ratio) to standard rehabilitation therapy versus standard rehabilitation therapy plus Smart Glove use. All patients will be allowed to participate in any scheduled outpatient rehabilitation during the study.

The study consists of a 12-week intervention period and a 12-week follow-up period. During the 12-week intervention period all patients will receive their usual rehabilitation therapy, with their therapists documenting rehabilitation dose in a journal provided at the start of the study. In addition, subjects randomized to the Smart Glove therapy arm will be provided with a Smart Glove system, which includes the glove and tablet. Subjects will be instructed to use the system for at least one session per day for 5 days per week during the 12-week intervention period. Participants will present for in-person visits on weeks 6, 12, and 24 for blinded assessments by study coordinators. At the completion of the intervention period, subjects will return the Smart Glove and subjects in both arms of the study will only receive usual care during the 12-week follow-up period. Subjects will have a final assessment at week 24 (12 weeks after completing the intervention) to assess for persistence of effect.

All efficacy analyses are analyzed under the intention to treat principle. The primary efficacy outcome is the change in score on the Jebsen Taylor Hand Test between baseline and week 12. Secondary efficacy endpoints are changes in scores on the upper extremity Fugl-Meyer Scale, Stroke Impact Scale, and total dose of rehabilitation received during the 24-week intervention period. Persistence of the treatment effect will be tested by comparing changes in scores on the Jebsen Taylor Hand Test and Fugl-Meyer upper extremity score at 24 weeks between treatment groups
A device for cryogenic modeling of acute pancreatitis consists of Peltier element, thermoprobe and air cooler. One-stage Peltier element with larger cold-generating area of 160 mm2 and lesser height of 4 mm is used. The area of the base of the thermoprobe is the same as the area of cryogenerating surface of Peltier element. The probe is made of copper in cone-pyramidal shape with lateral surface area covered with insulating paint. The operating surface is designed in a shape of 20 mm2 circular area. To remove heat from the heated surface of Peltier element, the active cooling is used. The contact area of Peltier element with the probe and air cooler is treated with thermal paste.
Exosomes are multifunctional, cell-derived nanoscale membrane vesicles. Exosomes derived from certain mammalian cells have been developed as angiogenesis promoters for the treatment of myocardial ischemia-reperfusion injury, as they possess the capability to enhance endothelial cell proliferation, migration, and angiogenesis. However, the low yield of exosomes derived from mammalian cells limits their clinical applications. Therefore, we chose to extract exosome-like nanoparticles from the traditional Chinese medicine Salvia miltiorrhiza, which has been shown to promote angiogenesis. Salvia miltiorrhiza-derived exosome-like nanoparticles offer advantages, such as being economical, easily obtainable, and high-yielding, and have an ideal particle size, Zeta potential, exosome-like morphology, and stability. Salvia miltiorrhiza-derived exosome-like nanoparticles can enhance the cell viability of Human Umbilical Vein Endothelial Cells and can promote cell migration and improve the neovascularization of the cardiac tissues of myocardial ischemia-reperfusion injury, indicating their potential as angiogenesis promoters for the treatment of myocardial ischemia-reperfusion injury.